This article is more than 5 years old. Information may no longer be current.
Alcon enters agreement with ThromboGenics to gain non-US rights to ocriplasmin
Click Here to Manage Email Alerts
LEUVEN, Belgium — Alcon and ThromboGenics have forged a strategic agreement that gives Alcon exclusive marketing rights to ocriplasmin outside the United States, ThromboGenics announced in a news release.
As a result of the agreement, Alcon plans to introduce ocriplasmin in more than 40 countries. ThromboGenics will retain all U.S. rights to ocriplasmin and will market the drug in the U.S.
ThromboGenics will receive an upfront lump sum payment of €75 million and a subsequent €90 million in potential near-term payments. Long-term potential payments are expected to total €375 million.
Ocriplasmin, the first pharmacological treatment for symptomatic vitreomacular adhesion including macular hole, is currently under review by the European Medicines Agency. It is expected to be launched in the U.S. within the next 12 months, the release said.
"Today's collaborative deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside of the United States is a major milestone for ThromboGenics. We are pleased that Alcon has recognized the potential of ocriplasmin to change the way symptomatic [vitreomacular adhesion] including macular hole is treated," Patrik De Haes, MD, CEO of ThromboGenics, said in the release.